Srikala Sridhar, MD, MSc, from the University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel as a secondary treatment for urothelial cancer.
Srikala Sridhar, MD, MSc
Advertisement
Articles by Srikala Sridhar, MD, MSc
Advertisement
Latest Updated Articles
Dr. Sridhar on Nab-Paclitaxel in Urothelial CancerJanuary 10th 2013
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
4
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
5